spacer
home > epc > autumn 2003 > make or buy? a strategic assessment of the benefits of outsourcing
PUBLICATIONS
European Pharmaceutical Contractor

Make or Buy? A Strategic Assessment of the Benefits of Outsourcing

Outsourcing has many converts across the manufacturing sector. But rather than join the evangelical throng urging companies to shed assets and be born again as product designers, solutions providers, industry innovators or supply chain integrators, this article advises manufacturers to take more of an agnostic approach and not to regard outsourcing as a panacea for every ill.

On the surface, the arguments for outsourcing are compelling. Improved information technology and communication links, falling interaction costs and global access to vendors mean that manufacturers now can choose more freely than ever before how to structure their business. In one stroke, outsourcing seems to offer the chance to dump operational headaches and bottlenecks, sidestep labour conflicts and management deficiencies and secure immediate cost savings.

But, while it is undoubtedly true that outsourcing lightens a company's asset base, if manufacturers automatically assume that it is the solution they will be failing to address the core question - that of how to improve a company's performance and maximise value.

Statistics indicate that growing numbers of businesses are becoming disenchanted with outsourcing. Dun & Bradstreet report that 20 to 25 per cent of all outsourcing relationships fail within two years and 50 per cent fail within five, the costs of which are high. Possible ramifications for a company include one-time and year-on-year financial goals being missed, delays in outsourcing timelines, lowered workforce morale and productivity, dissatisfied customers, greater consumption of management resources and large switching costs should operations need to be brought back in-house.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Blair McCallum, Head of McKinsey & Company's Production System Design Centre (PSDC)

Blair McCallum is the Head of McKinsey & Company's Production System Design Centre (PSDC). He has worked at Toyota, where he was part of the team that developed the European supplier base, and was responsible for Toyota production system training throughout Europe.

In 1995, he moved to Rover Group as a Senior Manager and subsequently became General Manager responsible for the supplier base and its five main manufacturing plants. Since joining PSDC in August 1998, Blair has worked with UK manufacturing companies of varying sizes and across all sectors to help transform their production processes.

spacer
Blair McCallum
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma enters into Development and Manufacturing Agreement with Synklino

Vilnius, Lithuania, and Copenhagen, Denmark – December 18th 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Synklino, a company active in developing a therapeutic protein based therapy as treatment for cytomegalovirus (CMV) infection, announced today that they entered into a Development and Manufacturing Agreement for the recombinant fusion protein SYNx, which Synklino aims to bring into clinical trials.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement